In vivo, our results showed that BLM-induced pulmonary lesions and the expression of α-SMA were dose-dependently alleviated by ARN-3236 (Figs. 4E, 5F), supporting the therapeutic effects of this compound in pulmonary fibrosis. This evidence concerns the gene ACTA1 and pulmonary fibrosis.